TELA Bio (TELA) Cash & Equivalents (2018 - 2026)

TELA Bio has reported Cash & Equivalents for 9 years, with the latest figure at $30.4 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 13.02% year-over-year to $30.4 million in Q2 2026; TTM through Jun 2026 was $30.4 million, a 13.02% decrease from a year earlier, with the FY2025 full-year figure at $50.8 million, down 3.46% from the prior year.
• Cash & Equivalents was $30.4 million for Q2 2026 at TELA Bio, down from $39.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $65.3 million in Q2 2023, with the low at $17.3 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $40.0 million, with a median of $38.3 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents jumped 135.4% in 2023, then sank 70.27% in 2024.
• Over 5 years, Cash & Equivalents stood at $42.0 million in 2022, then advanced by 11.21% to $46.7 million in 2023, then gained by 12.71% to $52.7 million in 2024, then fell by 3.46% to $50.8 million in 2025, then slumped by 40.16% to $30.4 million in 2026.
• The last three Cash & Equivalents figures came in at $30.4 million (Q2 2026), $39.5 million (Q1 2026), and $50.8 million (Q4 2025), per Business Quant data.